Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2017

View Archived Issues

Anti-CD73 A-001421 shows antitumor activity in experimental tumor models

Novel technique of rapid and robust diagnosis of Alzheimer's disease and various other dementias

TargomiRs demonstrates early signs of activity in patients with malignant pleural mesothelioma

Phase III trial of upadacitinib in rheumatoid arthritis meets all endpoints

Infant Bacterial Therapeutics reports topline safety data from phase II study of IBP-9414

MK-3866 studied in patients with impaired renal function

DelMar Pharmaceuticals commences phase II study of VAL-083 in GBM

EMA grants orphan drug designation to seladelpar for primary biliary cholangitis

New oncolytic measles virus-mediated delivery of PD-1-targeting antibody for cancer treatment

Marinus Pharmaceuticals reports results from phase II study in CDKL5 disorder

BARDA awards contract to Summit Therapeutics to develop ridinilazole for CDI

GSK initiates phase I study of acute pancreatitis treatment GSK-3335065

2017 Lasker awards recognize significance of HPV vaccine, mTOR

East China University of Science and Technology patents EGFR inhibitors

Taiho Pharmaceutical identifies RET inhibitors

DiaMedica Therapeutics begins phase II study of DM-199

Cantargia initiates phase I/II trial of CAN-04 in solid malignant tumors

DENV glycoprotein EDIII variants reported in Albert Einstein College of Medicine patent

Merck KGaA compares MSB-11455 to Neulasta in phase I studies

Global Alliance for TB Drug Development initiates phase I study of TBA-7371

Phase III LIBERTY ASTHMA QUEST study of dupilumab meets primary endpoints

The Osaka University discloses reoviruses for treating fibrosis

New phase I trial evaluates M-3541 with radiotherapy in patients with solid tumors

Bayer enters kidney disease collaboration with Vanderbilt University Medical Center

New malaria trial explores modifications to vaccine regimen of RTS,S

HitGen and Takeda establish drug discovery research collaboration

Canalia launched in Japan for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D
BioWorld Science
Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.